The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
245 - It seems to be standard industry practice to post the Product Monographs for pharmaceutical drug products on the corporate websites. There are no ancillary messages provided with these, just the links to the full texts of the product monographs. In addition, these PMs are available through Health Canada's Drug Product Database to anyone who searches, and these are unrestricted. However, I understand that PAAB reviews company prepared websites specific to products, even if they only contain information straight from the PM without any editing. If it is okay to post the PMs on the corporate websites and other publically available portals, why do the designated product websites that only contain the PM information require PAAB review? Thanks!
Miscellaneous
1
Posts
1
Posters
348
Views
1
Watching
-
The unchanged product monograph on a corporate website is not considered advertising (provided of course there is no link to product promotion/advertising). In my experience, there would be little reason to create a stand-alone website for an unchanged monograph. In the context of a stand-alone product site, we are inherently promoting a product (would require gating). The landing is inherently promotional (within name, price and quantity of course). Besides, why create a website for something that is already on your corporate website. Something does not add up here. Call me if I've misunderstood your question.
